Valuation: Novartis AG

Capitalization 304B 263B 238B 229B 417B 27,931B 435B 2,818B 1,126B 13,382B 1,142B 1,117B 47,985B P/E ratio 2026 *
21.7x
P/E ratio 2027 * 19.4x
Enterprise value 337B 291B 264B 253B 462B 30,937B 482B 3,121B 1,247B 14,822B 1,264B 1,237B 53,149B EV / Sales 2026 *
5.83x
EV / Sales 2027 * 5.52x
Free-Float
87.19%
Yield 2026 *
2.77%
Yield 2027 * 2.89%
1 day-1.48%
1 week-6.36%
Current month-6.36%
1 month+1.87%
3 months+14.59%
6 months+19.43%
Current year+11.50%
1 week 121.78
Extreme 121.78
130.4
1 month 119.74
Extreme 119.74
131
Current year 107.68
Extreme 107.68
131
1 year 81.1
Extreme 81.1
131
3 years 73.74
Extreme 73.74
131
5 years 72.84
Extreme 72.84
131
10 years 65.09
Extreme 65.09
131
Manager TitleAgeSince
Chief Executive Officer 50 31/01/2018
Director of Finance/CFO 61 23/04/2013
Chief Tech/Sci/R&D Officer 64 15/05/2022
Director TitleAgeSince
Director/Board Member 68 31/12/2014
Director/Board Member 69 31/12/2015
Director/Board Member 61 31/12/2015
Change 5d. change 1-year change 3-years change Capi.($)
-1.43%-6.36%+22.85%+54.25% 304B
-1.20%-7.87%+6.19%+203.87% 878B
-1.10%-4.54%+43.01%+52.45% 577B
-1.48%-1.11%+8.90%+47.81% 411B
-3.09%-7.36%+12.32%+25.60% 359B
-1.60%-6.72%+20.54%+34.97% 305B
-1.37%-7.68%+21.61%+2.89% 287B
-0.79%-6.61%+14.06%+54.19% 198B
-0.92%-4.04%+23.18%+76.22% 180B
-0.51%+5.11%-59.17%-50.39% 171B
Average -1.48%-0.91%+11.35%+50.19% 367.05B
Weighted average by Cap. -1.56%-1.38%+14.88%+76.84%

Financials

2026 *2027 *
Net sales 57.79B 49.98B 45.26B 43.45B 79.25B 5,308B 82.74B 535B 214B 2,543B 217B 212B 9,118B 60.54B 52.36B 47.41B 45.52B 83.02B 5,560B 86.68B 561B 224B 2,664B 227B 222B 9,552B
Net income 13.98B 12.09B 10.95B 10.51B 19.17B 1,284B 20.02B 130B 51.77B 615B 52.48B 51.36B 2,206B 15.78B 13.65B 12.36B 11.87B 21.64B 1,449B 22.6B 146B 58.43B 694B 59.24B 57.97B 2,490B
Net Debt 32.73B 28.31B 25.63B 24.61B 44.88B 3,006B 46.86B 303B 121B 1,440B 123B 120B 5,164B 29.79B 25.76B 23.33B 22.4B 40.85B 2,736B 42.65B 276B 110B 1,311B 112B 109B 4,700B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
06/03/26 122.26 CHF -2.05% 1,468,038
05/03/26 124.82 CHF -2.24% 3,521,352
04/03/26 127.68 CHF +1.01% 3,479,655
03/03/26 126.40 CHF -2.74% 4,007,072
02/03/26 129.96 CHF -0.41% 3,782,083
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
159.39USD
Average target price
150.03USD
Spread / Average Target
-5.88%

Quarterly revenue - Rate of surprise